Document Detail


The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.
MedLine Citation:
PMID:  20560981     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background  Low high-density lipoprotein (HDL) cholesterol and particle concentration are risk factors for coronary heart disease in women. Tibolone lowers HDL cholesterol and HDL particle concentration, an effect that could be reversed by the peroxisome proliferator-activator receptor-α agonist fenofibrate. Objective  To assess the effects of fenofibrate on plasma HDL particles in postmenopausal women taking tibolone therapy. Design and participants  Randomized crossover study conducted in a women's health clinic. Fourteen postmenopausal women taking tibolone 2·5 mg daily for menopausal symptoms were randomized to either fenofibrate 160 mg daily or no treatment for 8 weeks, followed by a 3- week wash-out for fenofibrate and then crossed over to alternate therapy for another 8 weeks. The main outcome measure was changes in plasma HDL cholesterol concentration, apoA-I and apoA-II, LpA-I and LpA-I-A-II. Results  After 8 weeks of fenofibrate therapy, there was no change in HDL cholesterol, 1·13 ± 0·06 v 1·16 ± 0·06 mmol/l (P = 0·47) or apoA-I, 1·19 ± 0·05 v 1·20 ± 0·05 g/l (P = 0·23). LpA-I fell significantly 0·35 ± 0·03 v 0·29 ± 0·02 (P = 0·02) but there was a rise in apoA-II, 0·35 ± 0·01 v 0·39 ± 0·01 g/l (P = 0·01). There was a significant fall in total cholesterol, triglycerides, low-density lipoprotein cholesterol and apoB. Conclusion  In women taking tibolone, fenofibrate increases plasma apoA-II concentration and effects a redistribution of HDL subfractions but does not correct tibolone-induced changes in HDL cholesterol or HDL particle concentration. The mechanism and significance of this require further investigation.
Authors:
B G A Stuckey; P H R Barrett; J M Wagner; R A Hampton; D C Chan; S J Brown; G F Watts
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical endocrinology     Volume:  73     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2011-01-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  497-501     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Keogh Institute for Medical Research School of Medicine and Pharmacology, University of Western Australia Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2?years of life.
Next Document:  Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment ...